Browsing Tag
chronic kidney disease
24 posts
Boehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial
Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective…
November 5, 2023
Innovative CKD management: AstraZeneca’s Zibotentan/Dapagliflozin advances to Phase III
Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria…
November 5, 2023
Zydus Lifesciences, Sun Pharma to co-market Desidustat for CKD patients in India
Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited have announced a licensing agreement for the co-marketing of Desidustat,…
October 30, 2023
Jardiance receives FDA approval to tackle kidney disease and cardiovascular risks
The U.S. Food and Drug Administration (FDA) has granted approval for Jardiance (empagliflozin) 10 mg tablets, a significant…
October 2, 2023
FDA approves Gilead’s Veklury for COVID-19 patients with severe renal impairment
Gilead Sciences said that the US Food and Drug Administration (FDA) has approved a supplemental new drug application…
July 14, 2023
ProKidney to acquire manufacturing facility in North Carolina for REACT commercial production
ProKidney, a late clinical-stage cellular therapeutics company, has announced plans to acquire a 210,000 square foot facility and…
June 13, 2023
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington…
June 12, 2023
AstraZeneca wraps up $1.8bn acquisition of CinCor Pharma
AstraZeneca has closed the previously announced $1.8 billion acquisition of US biopharmaceutical company CinCor Pharma. Under the terms…
February 28, 2023
GSK gets Jesduvroq FDA approval for anaemia of chronic kidney disease
GSK has secured the approval of the US Food and Drug Administration (FDA) for the company’s Jesduvroq (daprodustat)…
February 4, 2023
AstraZeneca to acquire US biopharma company CinCor Pharma for $1.8bn
AstraZeneca has agreed to acquire CinCor Pharma for a transaction value of around $1.8 billion, which includes an…
January 10, 2023